What is Liquid Biopsy?  

    Cancer detection and monitoring method

    Liquid Biopsy, also known as fluid biopsy, is a significant branch of in vitro diagnosis that is primarily based on blood or other body fluid for disease analysis and monitoring, such as cancer. With a simple blood draw, circulating tumor biomarkers in the blood sample provide information on tumor progression and treatment efficacy, and guiding personalized precision medication direction. Compared with traditional tissue biopsy, liquid biopsy has provided additional benefits of real-time monitoring, avoid unrepresentative sampling in heterogenous tumor, and provides comprehensive clinical information.

    Liquid Biopsy is a branch of in vitro diagnostics that analyses and diagnoses diseases such as cancer through the use of body liquids like blood or urine. It was rated as one of the “Breakthrough Technologies 2015” by MIT Technology Review.

    Compared to traditional tissue biopsy, liquid biopsy is equipped with unique advantages like real-time monitoring, ability to overcome tumor heterogeneity, and comprehensive diagnostic information. Currently, in clinical researches, liquid biosy mainly includes tests for CTC (Circulating Tumor Cell), ctDNA (Circulating Tumor DNA), exosomes, and Circulating miRNA etc. In comparison to traditional methods like observation of clinical symptoms or diagnostic imaging, using liquid biopsy can predict the risk of cancer earlier, enabling “Early discovery, early screening, early treatment”.

What is Circulating miRNA?

microRNAs or miRNAs are small RNA molecules that are non-coding and have important effects on gene expression, often inhibitory.  By binding to mRNAs in the cells, the microRNAs inhibit DNA functioning, thus affecting important life functions in a cell. In many cancer types, miRNAs production is upregulated, converting an ordinary cell into a cancerous one. Additionally, these miRNAs can be transported outside the cell, in the tumour environment, in sacs/vesicles called 'exosomes'. The presence of a high number of exosomal miRNAs has been associated with the spread of certain types of cancer in the body. Isolation and detection of miRNAs from a patient’s blood can help in early cancer diagnosis, without the need for invasive surgeries.

What is Circulating Tumor Cell (CTC)?

Circulating tumor cell (CTCs) are the cancer cells that have detached from the primary tumor or metastatic tumor into circulatory system during tumor progression or metastases. CTC provides comprehensive information of cancer in cellular, genetics and protein levels. Hence, CTC detection is an effective tool for earlier detection, evaluation of therapeutic efficacy, individual precision medicine selection, drug resistance detection, earlier tumor recurrence evaluation and real-time monitoring of cancer.

How can we detect CTCs in blood?

Cellomics CTC detection Platform - New generation of CTC viable Cell Sorting.

The CTC detection platform has employed the leading microfluidic chip technology that select CTCs extensively by cell size, cell shape and multiple surface biomarkers. This technology has combined the physical, chemical and biological properties of CTCs to uphold the high sensitivity, high specificity and high accuracy of CTC detection.


What is the bottleneck of commonly used monitoring methods?

Surgical removal of the tumor is a common way of treating cancer. However, even if the tumor is removed, cancer cells may remain in the body causing the disease to recur. Currently, patients undergo regular physical examination, imaging tests, and blood tests, allowing doctors to monitor the patients’ status and decide whether further treatment is needed.

What does real-time monitoring reveal?

Our technology can not only be used for early cancer screening but also helps in disease monitoring for patients with known cancer (solid tumor). The result obtained can tell doctors whether the effect of treatment is promising or not and whether a switch into another treatment plan is required. Since only 4 ml of blood is needed for our test, a patient's health and condition can be monitored more frequently than in traditional methods.

Our Solution

Our Solution


○ The CTC MntDx kit provides all 

   the reagents for CTC counting 

   and Typing .

Buffer Solution

Wash Buffer

Blocking Buffer

Fixation Buffer

Staining Solution C - uses antibody CD45 to distinguish white blood cells and CTCs.

Staining Solution D - uses antibody DAPI to stain cells.

Staining Solution E - uses antibody EpCAM to show the epithelial phenotype of the CTC.

The reagent in this kit is enough for 20 CTC tests.

Dynamic monitoring:

Yu, M., Bardia, A., Wittner, B. S., Stott, S. L.,et.al. (2013). Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science (New York, N.Y.), 339(6119), 580–584. https://doi.org/10.1126/science.1228522

Keller, L., & Pantel, K. (2019). Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells. Nature reviews. Cancer, 19(10), 553–567. https://doi.org/10.1038/s41568-019-0180-2

Zhang, Y., Li, J., Wang, L., et al. (2019). Clinical significance of detecting circulating tumor cells in patients with esophageal squamous cell carcinoma by EpCAMindependent enrichment and immunostainingfluorescence in situ hybridization. Molecular medicine reports, 20(2), 1551–1560. https://doi.org/10.3892/mmr.2019.10420

Shishido, S. N., Carlsson, A., Nieva, J., et.al. (2019). Circulating tumor cells as a response monitor in stage IV non-small cell lung cancer. Journal of translational medicine, 17(1), 294. https://doi.org/10.1186/s12967-019-2035-8

Balakrishnan, A., Koppaka, D., Anand, A., et.al. (2019). Circulating Tumor Cell cluster phenotype allows monitoring response to treatment and predicts survival. Scientific reports, 9(1), 7933. https://doi.org/10.1038/s41598-019-44404-y

Chen, Y., Li, S., Li, W., et.al. (2019). Circulating tumor cells undergoing EMT are poorly correlated with clinical stages or predictive of recurrence in hepatocellular carcinoma. Scientific reports, 9(1), 7084. https://doi.org/10.1038/s41598-019-43572-1

Bielčiková, Z., Jakabová, A., Pinkas, M., et.al. (2017). Circulating tumor cells: what we know, what do we want to know about them and are they ready to be used in clinics?. American journal of translational research, 9(6), 2807–2823.

EM ratio:

Yu, M., Bardia, A., Wittner, B. S., Stott, S. L.,et.al. (2013). Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science (New York, N.Y.), 339(6119), 580–584. https://doi.org/10.1126/science.1228522

Chen, Y., Li, S., Li, W. et al. (2019). Circulating tumor cells undergoing EMT are poorly correlated with clinical stages or predictive of recurrence in hepatocellular carcinoma. Sci Rep 9, 7084. https://doi.org/10.1038/s41598-019-43572-1

Fici, P., Gallerani, G., Morel, A. P.,et.al. (2017). Splicing factor ratio as an index of epithelial-mesenchymal transition and tumor aggressiveness in breast cancer. Oncotarget, 8(2), 2423–2436. https://doi.org/10.18632/oncotarget.13682

Polioudaki, H., Agelaki, S., Chiotaki, R. et al. (2015). Variable expression levels of keratin and vimentin reveal differential EMT status of circulating tumor cells and correlation with clinical characteristics and outcome of patients with metastatic breast cancer. BMC cancer, 15, 399. https://doi.org/10.1186/s12885-015-1386-7

 This kit is recommended for test of cancer patients or cancer rehabilitants for real-time monitoring of treatment efficacy and evaluate risk of metastasis 



CTC 100 Sorter





The Team




Contact Us

Email: info@cellomicsbio.com

Tel: +86-0755-28378001

Copyright © 2020 Cellomics All Rights Reserved

Copyright © 2020 Cellomics All Rights Reserved